Evonik stock rises 4.3 percent as restructuring expands

Evonik stock (ISIN DE000EVNK013) rose to EUR 17.98 on Xetra on September 22, 2026, a gain of 4.3 percent from the previous close of EUR 17.24. The move followed the announcement of the second phase of the group's restructuring programme, which is scheduled to run from 2027 through 2029.

Restructuring adds 3,200 cuts

According to Global Banking and Finance on September 22, 2026, Evonik plans to eliminate 3,200 positions worldwide between 2027 and 2029, including approximately 2,150 jobs in Germany. The plan also includes the divestment of Oxeno and Syneqt.

The restructuring phase extends a programme launched in 2024 and links further cost reductions with a strategic shift toward growth. Investing.com reported on September 22, 2026, that the company had not changed its 2026 outlook in connection with the announcement.

Stock remains below yearly high

The Xetra price of EUR 17.98 leaves the shares EUR 1.23 below the 52-week high of EUR 19.21 and EUR 5.49 above the 52-week low of EUR 12.49, both reported on September 22, 2026. The comparison shows that the daily reaction was strong, while the stock had not yet regained its yearly peak.

Marketscreener listed Evonik's Xetra quotation at EUR 17.76 and a 3.02 percent gain during its September 22, 2026 market snapshot, with volume of 6.2 million shares and market capitalization of EUR 8.03 billion. The different intraday values reflect the time of the respective quotation.

Price closes near the upper range

Evonik stock closed at EUR 17.98 on Xetra on September 22, 2026, up 4.3 percent from EUR 17.24. The next investor test is whether the restructuring plan can convert the planned workforce reduction and divestments into measurable earnings improvement through 2029.

More news and analyses on Evonik stock